Insights into the molecular mechanisms of plaque rupture and thrombosis

Indian Heart Journal

Volumn 57, Issue 1, 2005, Pages 21-30

  Shah, Prediman K ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b CEDARS SINAI MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AORTA RUPTURE; ATHEROSCLEROTIC PLAQUE; GENE OVEREXPRESSION; HUMAN; INFLAMMATION; MOLECULAR MECHANICS; PATHOPHYSIOLOGY; PHENOTYPE; REVIEW; THROMBOSIS;

ANIMALS; ARTERIOSCLEROSIS; CORONARY THROMBOSIS; DISEASE PROGRESSION; HUMANS; INFLAMMATION; LIPID METABOLISM; MACROPHAGES; RUPTURE;

EID: 17644398144     PISSN: 00194832     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (155)

1. Murray CJ, Lopez AD. Global mortality, disability and contribution of risk factors: Global Burden of Disease Study. Lancet 1997; 349: 1436-1442
2. Falk E, Shah PK, Fuster V. Coronary plaque disruption. Circulation 1995; 92: 657-671
3. Virmani R, Burke AP, Farb A. Plaque rupture and plaque erosion. Thromb Haemost 1999; 82 (Suppl 1): 1-3
4. Shah PK. Pathophysiology of coronary thrombosis: role of plaque rupture and plaque erosion. Prog Cardiovas Dis 2002; 44: 357-368
5. Libby P. Current concepts of the pathogenesis of the acute coronary syndromes. Circulation 2001; 104: 365-372
6. DeWood MA, Spores J, Notske R, Mouser LT, Burroughs R, Golden MS, et al. Prevalence of total coronary occlusion during the early hours of transmural myocardial infarction. N Engl J Med 1980; 303: 897-902
7. DeWood MA, Spores J, Hensley GR, Simpson CS, Eugster GS, Sutherland KI, et al. Coronary arteriographic findings in acute transmural myocardial infarction. Circulation 1983; 68: 139-149
8. DeWood MA, Stifter WF, Simpson CS, Spores J, Eugster GS, Judge TP, et al. Coronary arteriographic findings soon after non-Q-wave myocardial infarction. N Engl J Med 1986; 315: 417-423
9. Levin DC, Fallon JT. Significance of the angiographic morphology of localized coronary stenoses: histopathologic correlations. Circulation 1982; 66: 316-320
10. Sherman CT, Litvack F, Grundfest W, Lee M, Hickey A, Chaux A, et al. Coronary angioscopy in patients with unstable angina pectoris. N Engl J Med 1986; 315: 913-919
11. Kruskal JB, Commerford PJ, Franks JJ, Kirsch RE. Fibrin and fibrinogen-related antigens in patients with stable and unstable coronary artery disease. N Engl J Med 1987; 317: 1361-1365
12. Folts JD. Platelet aggregation in stenosed coronary or cerebral arteries: a mechanism for sudden death? Wis Med J 1980; 79: 24-26
13. Davies MJ, Thomas A. Thrombosis and acute coronary-artery lesions in sudden cardiac ischemic death. N Engl J Med 1984; 310: 1137-1140
14. Falk E. Plaque rupture with severe pre-existing stenosis precipitating coronary thrombosis. Characteristics of coronary atherosclerotic plaques underlying fatal occlusive thrombi. Br Heart J 1983; 50: 127-134
15. Ambrose JA, Winters SL, Stern A, Eng A, Teichholz LE, Gorlin R, et al. Angiographic morphology and the pathogenesis of unstable angina pectoris. J Am Coll Cardiol 1985; 5: 609-616
16. Ambrose JA, Winters SL, Arora RR, Haft JI, Goldstein J, Rentrop KP, et al. Coronary angiographic morphology in myocardial infarction: a link between the pathogenesis of unstable angina and myocardial infarction. J Am Coll Cardiol 1985; 6: 1233-1238
17. Gorlin R, Fuster V, Ambrose JA. Anatomic-physiologic links between acute coronary syndromes. Circulation 1986; 74: 6-9
18. Friedman M. Pathogenesis of coronary thrombosis, intramural and intraluminal hemorrhage. Adv Cardiol 1970; 4: 20-46
19. Friedman M. The pathogenesis of coronary plaques, thromboses, and hemorrhages: an evaluative review. Circulation 1975; 52: III34-III40
20. Constantinides P. Atherosclerosis - a general survey and synthesis. Surv Synth Pathol Res 1984; 3: 477-498
21. Ambrose JA, Hjemdahl-Monsen C, Borrico S, Sherman W, Cohen M, Gorlin R, et al. Quantitative and qualitative effects of intracoronary streptokinase in unstable angina and non-Q wave infarction. J Am Coll Cardiol 1987; 9: 1156-1165
22. Ambrose JA, Winters SL, Arora RR, Eng A, Riccio A, Gorlin R, et al. Angiographic evolution of coronary artery morphology in unstable angina. J Am Coll Cardiol 1986; 7: 472-478
23. Ambrose JA, Monsen C. Significance of intraluminal filling defects in unstable angina. Am J Cardiol 1986; 57: 1003-1004
24. Little WC, Constantinescu M, Applegate RJ, Kutcher MA, Burrows MT, Kahl ER, et al. Can coronary angiography predict the site of a subsequent myocardial infarction in patients with mild-to-moderate coronary artery disease? Circulation 1988; 78: 1157-1166
25. Hackett D, Davies G, Maseri A. Pre-existing coronary stenoses in patients with first myocardial infarction are not necessarily severe. Eur Heart J 1988; 9: 1317-1323
26. Giroud D, Li JM, Urban P, Meier B, Rutishauer W. Relation of the site of acute myocardial infarction to the most severe coronary arterial stenosis at prior angiography. Am J Cardiol 1992; 69: 729-732
27. Brown G, Albers JJ, Fisher LD, Schaefer SM, Lin JT, Kaplan C, et al. Regression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels of apolipoprotein B. N Engl J Med 1990; 323: 1289-1298
28. Naqvi TZ, Hachamovitch R, Berman D, Buchbinder N, Kiat H, Shah PK. Does the presence and site of myocardial ischemia on perfusion scintigraphy predict the occurrence and site of future myocardial infarction in patients with stable coronary artery disease? Am J Cardiol 1997; 79: 1521-1524
29. Shah PK. Plaque size, vessel size and plaque vulnerability: bigger may not be better. J Am Coll Cardiol 1998; 32: 663-664
30. Schoenhagen P, Ziada KM, Kapadia SR, Crowe TD, Nissen SE, Tuzcu EM. Extent and direction of arterial remodeling in stable versus unstable coronary syndromes: an intravascular ultrasound study. Circulation 2000; 101: 598-603
31. von Birgelen C, Klinkhart W, Mintz GS, Popatheodorou A, Herrmann J, Baumagart D, et al. Plaque distribution and vascular remodeling of ruptured and nonruptured coronary plaques in the same vessel: an intravascular ultrasound study in vivo. J Am Coll Cardiol 2001; 37: 1864-1870
32. Takano M, Mizuno K, Okamatsu K, Yokoyama S, Ohba T, Sakai S. Mechanical and structural characteristics of vulnerable plaques: analysis by coronary angioscopy and intravascular ultrasound. J Am Coll Cardiol 2001; 38: 99-104
33. Loree HM, Kamm RD, Stringfellow RG, Lee RT. Effects of fibrous cap thickness on peak circumferential stress in model atherosclerotic vessels. Circ Res 1992; 71: 850-858
34. Varnava AM, Mills PG, Davies MJ. Relationship between coronary artery remodeling and plaque vulnerability. Circulation 2002; 105: 939-943
35. Guyton JR, Klemp KF. Development of the lipid-rich core in human atherosclerosis. Arterioscler Thromb Vasc Biol 1996; 16: 4-11
36. Richardson PD, Davies MJ, Born GV. Influence of plaque configuration and stress distribution on fissuring of coronary atherosclerotic plaques. Lancet 1989; 2: 941-944
37. Davies MJ, Richardson PD, Woolf N, Katz DR, Mann J. Risk of thrombosis in human atherosclerotic plaques: role of extracellular lipid, macrophage, and smooth muscle cell content. Br Heart J 1993; 69: 377-381
38. Felton CV, Crook D, Davies MJ, Oliver MF. Relation of plaque lipid composition and morphology to the stability of human aortic plaques. Arterioscler Thromb Vasc Biol 1997; 17: 1337-1345
39. Burleigh MC, Briggs AD, Lendon CL, Davies MJ, Born GV, Richardson PD. Collagen types I and III, collagen content, GAGs and mechanical strength of human atherosclerotic plaque caps: span-wise variations. Atherosclerosis 1992; 96: 71-81
40. Moreno PR, Falk E, Palacios IF, Newell JB, Fuster V, Fallon JT. Macrophage infiltration in acute coronary syndromes. Implications for plaque rupture. Circulation 1994; 90: 775-778
41. Moreno PR, Bernardi VH, Lopez-Cuellar J, Murcia AM, Palacios IF, Gold HK, et al. Macrophages, smooth muscle cells, and tissue factor in unstable angina. Implications for cell-mediated thrombogenicity in acute coronary syndromes. Circulation 1996; 94: 3090-3097
42. Lendon CL, Davies MJ, Born GV, Richardson PD. Atherosclerotic plaque caps are locally weakened when macrophages density is increased. Atherosclerosis 1991; 87: 87-90
43. Depre C, Havaux X, Wijns W. Neovascularization in human coronary atherosclerotic lesions. Cathet Cardiovasc Diagn 1996; 39: 215-220
44. Tenaglia AN, Peters KG, Sketch MH Jr, Annex BH. Neovascularization in atherectomy specimens from patients with unstable angina: implications for pathogenesis of unstable angina. Am Heart J 1998; 135: 10-14
45. Feng B, Yao PM, Li Y, Devlin CM, Zhang D, Harding HP, et al. The endoplasmic reticulum is the site of cholesterol-induced cytotoxicity in macrophages. Nat Cell Biol 2003; 5: 781-792
46. Kolodgie FD, Gold HK, Burke AP, Fowler DR, Kruth HS, Weber DK, et al. Intraplaque hemorrhage and progression of coronary atheroma. N Engl J Med 2003;349:2316-2325
47. Cheng GC, Loree HM, Kamm RD, Fishbein MC, Lee RT. Distribution of circumferential stress in ruptured and stable atherosclerotic lesions. A structural analysis with histopathological correlation. Circulation 1993; 87: 1179-1187
48. Loree HM, Tobias BJ, Gibson LJ, Kamm RD, Small DM, Lee RT. Mechanical properties of model atherosclerotic lesion lipid pools. Arterioscler Thromb 1994; 14: 230-234
49. Huang H, Virmani R, Younis H, Burke AP, Kamm RD, Lee RT. The impact of calcification on the biomechanical stability of atherosclerotic plaques. Circulation 2001; 103: 1051-1056
50. Faber BC, Cleutjens KB, Niessen RL, Aarts PL, Boon W, Greenberg AS, et al. Identification of genes potentially involved in rupture of human atherosclerotic plaques. Circ Res 2001; 89: 547-554
51. Essler M, Retzer M, Bauer M, Zangl KJ, Tigyi G, Siess W. Stimulation of platelets and endothelial cells by mildly oxidized LDL proceeds through activation of lysophosphatidic acid receptors and the Rho/Rho-kinase pathway. Inhibition by lovastatin. Ann NY Acad Sci 2000; 905: 282-286
52. Toschi V, Gallo R, Lettino M, Fallon JT, Gertz SD, Fernandez-Ortiz A, et al. Tissue factor modulates the thrombogenicity of human atherosclerotic plaques. Circulation 1997; 95: 594-599
53. Mallat Z, Hugel B, Ohan J, Leseche G, Freyssinet JM, Tedgui A. Shed membrane microparticles with procoagulant potential in human atherosclerotic plaques: a role for apoptosis in plaque thrombogenicity. Circulation 1999; 99: 348-353
54. Badimon JJ, Lettino M, Toschi V, Fuster V, Berrozpe M, Chesebro JH, et al. Local inhibition of tissue factor reduces the thrombogenicity of disrupted human atherosclerotic plaques: effects of tissue factor pathway inhibitor on plaque thrombogenicity under flow conditions. Circulation 1999; 99: 1780-1787
55. Fernandez-Ortiz A, Badimon JJ, Falk E, Fuster V, Meyer B, Mailhac A, et al. Characterization of the relative thrombogenicity of atherosclerotic plaque components: implications for consequences of plaque rupture. J Am Coll Cardiol 1994; 23: 1562-1569
56. van der Wal AC, Becker AE, van der Loos CM, Das PK. Site of intimal rupture or erosion of thrombosed coronary atherosclerotic plaques is characterized by an inflammatory process irrespective of the dominant plaque morphology. Circulation 1994; 89: 36-44
57. Kovanen PT. The mast cell-a potential link between inflammation and cellular cholesterol deposition in atherogenesis. Eur Heart J 1993; 14 (Suppl K): 105-117
58. Kovanen PT, Kaartinen M, Paavonen T. Infiltrates of activated mast cells at the site of coronary atheromatous erosion or rupture in myocardial infarction. Circulation 1995; 92: 1084-1088
59. Kaartinen M, van der Wal AC, van der Loos CM, Piek JJ, Koch KT, Becker AE, et al. Mast cell infiltration in acute coronary syndromes: implications for plaque rupture. J Am Coll Cardiol 1998; 32: 606-612
60. Laine P, Kaartinen M, Penttila A, Panula P, Paavonen T, Kovanen PT. Association between myocardial infarction and the mast cells in the adventitia of the infarct-related coronary artery. Circulation 1999; 99: 361-369
61. Libby P. Inflammation in atherosclerosis. Nature 2002; 420: 868-874
62. Barger AC, Beeuwkes R 3rd, Lainey LL, Silverman KJ. Hypothesis: vasa vasorum and neovascularization of human coronary arteries. A possible role in the pathophysiology of atherosclerosis. N Engl J Med 1984; 310: 175-177
63. Kamat BR, Galli SJ, Barger AC, Lainey LL, Silverman KJ. Neovascularization and coronary atherosclerotic plaque: cinematographic localization and quantitative histologic analysis. Hum Pathol 1987; 18: 1036-1042
64. Barger AC, Beeuwkes R 3rd. Rupture of coronary vasa vasorum as a trigger of acute myocardial infarction. Am J Cardiol 1990; 66: 41G-43G
65. Heistad DD, Armstrong ML. Blood flow through vasa vasorum of coronary arteries in atherosclerotic monkeys. Arteriosclerosis 1986; 6: 326-331
66. Williams JK, Heistad DD. The vasa vasorum of the arteries. J Mal Vasc 1996; 21: 266-269
67. Kwon HM, Sangiorgi G, Ritman EL, McKenna C, Holmes DR Jr, Schwartz RS, et al. Enhanced coronary vasa vasorum neovascularization in experimental hypercholesterolemia. J Clin Invest 1998; 101: 1551-1556
68. Gojova A, Brun V, Esposito B, Cottrez F, Gourdy P, Ardouin P, et al. Specific abrogation of transforming growth factor-beta signaling in T cells alters atherosclerotic lesion size and composition in mice. Blood 2003; 102: 4052-4058
69. Robertson AL, Rudling M, Zhou X, Gorelik L, Flavell RA, Hansson GK. Disruption of TGF-beta signaling in T cells accelerates atherosclerosis. J Clin Invest 2003; 112: 1342-1350
70. Tedgui A, Mallat Z. Anti-inflammatory mechanisms in the vascular wall. Circ Res 2001; 88: 877-887
71. Xu XH, Shah PK, Faure E, Equils O, Thomas L, Fishbein MC, et al. Toll-like receptor-4 is expressed by macrophages in murine and human lipid-rich atherosclerotic plaques and upregulated by oxidized LDL. Circulation 2001; 104: 3103-3108
72. Michelsen KS, Wong MH, Shah PK, Zhang W, Yano J, Doherty TM, et al. Lack of Toll-like receptor 4 or myeloid differentiation factor 88 reduces atherosclerosis and alters plaque phenotype in mice deficient in apolipoprotein E. Proc Natl Acad Sci USA 2004; 101: 10679-10684
73. Henney AM, Wakeley PR, Davies MJ, Foster K, Hembry R, Murphy G, et al. Localization of stromelysin gene expression in atherosclerotic plaques by in situ hybridization. Proc Natl Acad Sci USA 1991; 88: 8154-8158
74. Galis ZS, Sukhova GK, Lark MW Libby P. Increased expression of matrix metalloproteinases and matrix degrading activity in vulnerable regions of human atherosclerotic plaques. J Clin Invest 1994; 94: 2493-2503
75. Brown DL, Hibbs MS, Kearney M, Loushin C, Isner JM. Identification of 92-kD gelatinase in human coronary atherosclerotic lesions. Association of active enzyme synthesis with unstable angina. Circulation 1995; 91: 2125-2131
76. Nikkari ST, O'Brien KD, Ferguson M, Hatsukami T, Welgus HG, Alpers CE, et al. Interstitial collagenase (MMP-1) expression in human carotid atherosclerosis. Circulation 1995; 92: 1393-1398
77. Li Z, Li L, Zielke HR, Cheng L, Xiao R, Crow MT, et al. Increased expression of 72-kd type IV collagenase (MMP-2) in human aortic atherosclerotic lesions. Am J Pathol 1996; 148: 121-128
78. Galis ZS, Sukhova GK, Libby P. Microscopic localization of active proteases by in situ zymography: detection of matrix metalloproteinase activity in vascular tissue. FASEB J 1995; 9: 974-980
79. Xu XP, Meisel SR, Ong JM, Kaul S, Cercek B, Rajavashisth TB, et al. Oxidized low-density lipoprotein regulates matrix metalloproteinase-9 and its tissue inhibitor in human monocyte-derived macrophages. Circulation 1999; 99: 993-998
80. Rajavashisth TB, Xu XP, Jovinge S, Meisel S, Xu XO, Chai NN, et al. Membrane type 1 matrix metalloproteinase expression in human atherosclerotic plaques: evidence for activation by proinflammatory mediators. Circulation 1999; 99: 3103-3109
81. Rajavashisth TB, Liao JK, Galis ZS, Tripathi S, Laufs U, Tripathi J, et al. Inflammatory cytokines and oxidized low density lipoproteins increase endothelial cell expression of membrane type 1-matrix metalloproteinase. J Biol Chem 1999; 274: 11924-11929
82. Herman MP, Sukhova GK, Libby P, Gerdes N, Tang N, Horton DB, et al. Expression of neutrophil collagenase (matrix metalloproteinase-8) in human atheroma: a novel collagenolytic pathway suggested by transcriptional profiling. Circulation 2001; 104: 1899-1904
83. Shah PK, Falk E, Badimon JJ, Fernandez-Ortiz A, Mailhac A, Villareal-Levy G, et al. Human monocyte-derived macrophages induce collagen breakdown in fibrous caps of atherosclerotic plaques. Potential role of matrix-degrading metalloproteinases and implications for plaque rupture. Circulation 1995; 92: 1565-1569
84. Shah PK. Role of inflammation and metalloproteinases in plaque disruption and thrombosis. Vasc Med 1998; 3: 199-206
85. Sukhova GK, Schonbeck U, Rabkin E, Schoen FJ, Poole AR, Billinghurst RC, et al. Evidence for increased collagenolysis by interstitial collagenases -1 and -3 in vulnerable human atheromatous plaques. Circulation 1999; 99: 2503-2509
86. Lee RT, Schoen FJ, Loree HM, Lark MW, Libby P. Circumferential stress and matrix metalloproteinase 1 in human coronary atherosclerosis. Implications for plaque rupture. Arterioscler Thromb Vasc Biol 1996; 16: 1070-1073
87. Galis ZS, Muszynski M, Sukhova GK, Simon-Morrissey E, Libby P. Enhanced expression of vascular matrix metalloproteinases induced in vitro by cytokines and in regions of human atherosclerotic lesions. Ann NY Acad Sci 1995; 748: 501-507
88. Galis ZS, Sukhova GK, Kranzhofer R, Clark S, Libby P. Macrophage foam cells from experimental atheroma constitutively produce matrix-degrading proteinases. Proc Natl Acad Sci USA 1995: 92: 402-406
89. Kol A, Sukhova GK, Lichtman AH, Libby P. Chlamydial heat shock protein 60 localizes in human atheroma and regulates macrophage tumor necrosis factor-alpha and matrix metalloproteinase expression. Circulation 1998; 98: 300-307
90. Mach F, Schonbeck U, Fabunmi RP, Murphy C, Atkinson E, Bonnefoy JY, et al. T lymphocytes induce endothelial cell matrix metalloproteinase expression by a CD40L-dependent mechanism: implications for tubule formation. Am J Pathol 1999; 154: 229-238
91. Schonbeck U, Mach F, Sukhova GK, Murphy C, Bonnefoy JY, Fabunmi RP, et al. Regulation of matrix metalloproteinase expression in human vascular smooth muscle cells by T lymphocytes: a role for CD40 signaling in plaque rupture? Circ Res 1997; 81: 448-454
92. Wallner K, Li C, Shah PK, Fishbein MC, Forrester JS, Kaul S, et al. Tenascin-C is expressed in macrophage-rich human coronary atherosclerotic plaque. Circulation 1999; 99: 1284-1289
93. Sukhova GK, Shi GP, Simon DI, Chapman HA, Libby P. Expression of the elastolytic cathepsins S and K in human atheroma and regulation of their production in smooth muscle cells. J Clin Invest 1998; 102: 576-583
94. Shi GP, Sukhova GK, Grubb A, Ducharme A, Rhode LH, Lee RT, et al. Cystatin C deficiency in human atherosclerosis and aortic aneurysms. J Clin Invest 1999; 104: 1191-1197
95. Bennett MR, Evan GI, Schwartz SM. Apoptosis of human vascular smooth muscle cells derived from normal vessels and coronary atherosclerotic plaques. J Clin Invest 1995; 95: 2266-2274
96. Bjorkerud S, Bjorkerud B. Apoptosis is abundant in human atherosclerotic lesions, especially in inflammatory cells (macrophages and T cells), and may contribute to the accumulation of gruel and plaque instability. Am J Pathol 1996; 149: 367-380
97. Kockx MM, Knaapen MW The role of apoptosis in vascular disease. J Pathol 2000; 190: 267-280
98. Ihling C, Haendeler J, Menzel G, Hess RD, Fraedrich G, Schaefer HE, et al. Co-expression of p53 and MDM2 in human atherosclerosis: implications for the regulation of cellularity of atherosclerotic lesions. J Pathol 1998; 185: 303-312
99. Crisby M, Kallin B, Thyberg J, Zhivotovsky B, Orrenius S, Kostulas V, et al. Cell death in human atherosclerotic plaques involves both oncosis and apoptosis. Atherosclerosis 1997; 130: 17-27
100. Bennett MR. Apoptosis of vascular smooth muscle cells in vascular remodelling and atherosclerotic plaque rupture. Cardiovasc Res 1999; 41: 361-368
101. Galle J, Heermeier K, Wanner C. Atherogenic lipoproteins, oxidative stress, and cell death. Kidney Int Suppl 1999; 71: S62-S65
102. Vieira O, Escargueil-Blanc I, Jurgens G, Borner C, Almeida L, Salvayre R, et al. Oxidized LDLs alter the activity of the ubiquitin-proteasome pathway: potential role in oxidized LDL-induced apoptosis. FASEB J 2000; 14: 532-542
103. Rossig L, Dimmeler S, Zeiher AM. Apoptosis in the vascular wall and atherosclerosis. Basic Res Cardiol 2001; 96: 11-22
104. Geng YJ, Wu Q, Muszynski M, Hansson GK, Libby P. Apoptosis of vascular smooth muscle cells induced by in vitro stimulation with interferon-gamma, tumor necrosis factor-alpha, and interleukin-1 beta. Arterioscler Thromb Vasc Biol 1996; 16: 19-27
105. Geng YJ, Henderson LE, Levesque EB, Muszynski M, Libby P. Fas is expressed in human atherosclerotic intima and promotes apoptosis of cytokine-primed human vascular smooth muscle cells. Arterioscler Thromb Vasc Biol 1997; 17: 2200-2208
106. Mallat Z, Tedgui A. Apoptosis in the vasculature; mechanisms and functional importance. Br J Pharmacol 2000; 130: 947-962
107. Wallner K, Li C, Shah PK, Wu KJ, Schwartz SM, Sharifi BG. EGF-like domain of tenascin-C is proapoptotic for cultured smooth muscle cells. Arterioscler Thromb Vasc Biol 2004; 24: 1416-1421
108. Kolmakova A, Kwiterovich P, Virgil D, Alaupovic P, Knight-Gibson C, Martin SF, et al. Apolipoprotein C-I induces apoptosis in human aortic smooth muscle cells via recruiting neutral sphingomyelinase. Arterioscler Thromb Vasc Biol 2004; 24: 264-269
109. Durand E, Scoazec A, Lafont A, Boddaert J, Al Hajzen A, Addad F, et al. In vivo induction of endothelial apoptosis leads to vessel thrombosis and endothelial denudation: a clue to the understanding of the mechanisms of thrombotic plaque erosion. Circulation. 2004; 109: 2503-2506
110. Sugiyama S, Kugiyama K, Aikawa M, Nakamura S, Ogawa H, Libby P. Hypochlorous acid, a macrophage product, induces endothelial apoptosis and tissue factor expression: involvement of myeloperoxidase-mediated oxidant in plaque erosion and thrombogenesis. Arterioscler Thromb Vasc Biol 2004; 24: 1309-1314
111. Abela GS, Picon PD, Friedl SE, Gebara OC, Miyamoto A, Federman M, et al. Triggering of plaque disruption and arterial thrombosis in an atherosclerotic rabbit model. Circulation 1995; 91: 776-784
112. Rekhter MD, Hicks GW, Brammer DW, Work CW, Kim JS, Gordon D, et al. Animal model that mimics atherosclerotic plaque rupture. Circ Res 1998; 83: 705-713
113. Caligiuri G, Levy B, Pernow J, Thoren P, Hansson GK. Myocardial infarction mediated by endothelin receptor signaling in hypercholesterolemic mice. Proc Natl Acad Sci USA 1999; 96: 6920-6924
114. Rosenfeld ME, Polinsky P, Virmani R, Kauser K, Rubanyi G, Schwartz SM. Advanced atherosclerotic lesions in the innominate artery of the Apo E knockout mouse. Arterioscler Thromb Vasc Biol 2000; 20: 2587-2592
115. Johnson JL, Jackson CL. Atherosclerotic plaque rupture in the apolipoprotein E knockout mouse. Atherosclerosis 2001; 154: 399-406
116. Lemaitre V, O'Byrne TK, Borczuk AC, Okada Y, Tall AR, D'Armiento J. Apo E knockout mice expressing human matrix metalloproteinase1 in macrophages have less advanced atherosclerosis. J Clin Invest 2001; 107: 1227-1234
117. Calara F, Silvestre M, Casanada F, Yuan N, Napoli C, Palinski W. Spontaneous plaque rupture and secondary thrombosis in apolipoprotein E- deficient and LDL receptor-deficient mice. J Pathol 2001; 195: 257-263
118. von der Thusen JH, van Vlijmen BJ, Hoeben RC, Kockx MM, van Berkel TJ, Al Biessen AI. Induction of atherosclerotic plaque rupture in Apo E-/- mice following adenovirus mediated transfer of p53 (Abstr). Circulation 2001; 104: 11-10
119. Muller JE, Tofler GH, Stone PH. Circadian variation and triggers of onset of acute cardiovascular disease. Circulation 1989; 79: 733-743
120. Muller JE. Morning increase of onset of myocardial infarction. Implications concerning triggering events. Cardiology 1989; 76: 96-104
121. Muller JE, Tofler GH. Triggering and hourly variation of onset of arterial thrombosis. Ann Epidemiol 1992; 2: 393-405
122. Willich SN, Jimenez AH, Tofler GH, DeSilva RA, Muller JE. Pathophysiology and triggers of acute myocardial infarction: clinical implications. Clin Investig 1992; 70: S73-S78
123. Willich SN, Maclure M, Mittleman M, Arntz HR, Muller JE. Sudden cardiac death. Support for a role of triggering in causation. Circulation 1993; 87: 1442-1450
124. Peters A, Dockery DW, Muller JE, Mittleman MA. Increased particulate air pollution and the triggering of myocardial infarction. Circulation 2001; 103: 2810-2815
125. Mittleman MA, Lewis RA, Maclure M, Sherwood JB, Muller JE. Triggering myocardial infarction by marijuana. Circulation 2001; 103: 2805-2809
126. Muller JE. Circadian variation and triggering of acute coronary events. Am Heart J 1999; 137: S1-S8
127. Muller JE. Triggering of cardiac events by sexual activity: findings from a case-crossover analysis. Am J Cardiol 2000; 86: 14F-18F
128. Goldstein JA, Demetriou D, Grines CL, Pica M, Shoukfeh M, O'Neill WW. Multiple complex coronary plaques in patients with acute myocardial infarction. N Engl J Med 2000; 343: 915-922
129. Matetzky S, Tani S, Kangavari S, Dimayuga P, Yano J, Xu H, et al. Smoking increases tissue factor expression in atherosclerotic plaques: implications for plaque thrombogenicity. Circulation 2000; 102: 602-604
130. Burke AP, Kolodgie FD, Farb A, Weber DK, Malcom GT, Smialek J, et al. Healed plaque ruptures and sudden coronary death: evidence that subclinical rupture has a role in plaque progression. Circulation 2001; 103: 934-940
131. Burke AP, Farb A, Malcom GT, Liang YH, Smialek J, Virmani R. Coronary risk factors and plaque morphology in men with coronary disease who died suddenly. N Engl J Med 1997; 336: 1276-1282
132. Farb A, Burke AP, Tang AL, Liang TY, Mannan P, Smialek J, et al. Coronary plaque erosion without rupture into a lipid core. A frequent cause of coronary thrombosis in sudden coronary death. Circulation 1996; 93: 1354-1363
133. Rauch U, Bonderman D, Bohrmann B, Badimon JJ, Himber J, Riederer MA, et al. Transfer of tissue factor from leukocytes to platelets is mediated by CD15 and tissue factor. Blood 2000; 96: 170-175
134. Mallat Z, Benamer H, Hugel B, Benessiano J, Steg PG, Freyssinet JM, et al. Elevated levels of shed membrane microparticles with procoagulant potential in the peripheral circulating blood of patients with acute coronary syndromes. Circulation 2000; 101: 841-843
135. Laszik ZG, Zhou XJ, Ferrell GL, Silva FG, Esmon CT. Down-regulation of endothelial expression of endothelial cell protein C receptor and thrombomodulin in coronary atherosclerosis. Am J Pathol 2001; 159: 797-802
136. Schwartz CJ, Valente AJ, Sprague EA, Kelley JL, Cayatte AJ, Mowery J. Atherosclerosis. Potential targets for stabilization and regression. Circulation 1992; 86: III117-23
137. Waters D. Plaque stabilization: a mechanism for the beneficial effect of lipid- lowering therapies in angiography studies. Prog Cardiovasc Dis 1994; 37: 107-20
138. Shah PK. Pathophysiology of plaque rupture and the concept of plaque stabilization. Cardiol Clin 2003; 21: 303-314
139. Shah PK. Mechanisms of plaque vulnerability and rupture. J Am Coll Cardiol 2003; 41: 15S-22S
140. Kullo IJ, Edwards WD, Schwartz RS. Vulnerable plaque: pathobiology and clinical implications. Ann Intern Med 1998; 129: 1050-1060
141. Lee RT. Plaque stabilization: the role of lipid lowering. Int J Cardiol 2000; 74(Suppl 1): S11-S15
142. Aikawa M, Rabkin E, Okada Y, Voglic SJ, Clinton SK, Brinckerhoff CE, et al. Lipid lowering by diet reduces matrix metalloproteinase activity and increases collagen content of rabbit atheroma: a potential mechanism of lesion stabilization. Circulation 1998; 97: 2433-2444
143. Aikawa M, Libby P. Lipid lowering reduces proteolytic and prothrombotic potential in rabbit atheroma. Ann N Y Acad Sci 2000; 902: 140-152
144. Aikawa M, Rabkin E, Sugiyama S, Voglic SJ, Fukumoto Y, Furukawa Y, et al. An HMG-CoA reductase inhibitor, cerivastatin, suppresses growth of macrophages expressing matrix metalloproteinases and tissue factor in vivo and in vitro. Circulation 2001; 103: 276-283
145. Fukumoto Y, Libby P, Rabkin E, Hill CC, Enomoto M, Hirouchï Y, et al. Statins alter smooth muscle cell accumulation and collagen content in established atheroma of watanabe heritable hyperlipidemic rabbits. Circulation 2001; 103: 993-999
146. Ameli S, Hultgardh-Nilsson A, Cercek B, Shah PK, Forrester JS, Ageland H, et al. Recombinant apolipoprotein A-I Milano reduces intimal thickening after balloon injury in hypercholesterolemic rabbits. Circulation 1994; 90: 1935-1941
147. Shah PK, Nilsson J, Kaul S, Fishbein MC, Ageland H, Hamsten A, et al. Effects of recombinant apolipoprotein A-I (Milano) on aortic atherosclerosis in apolipoprotein E-deficient mice. Circulation 1998; 97: 780-785
148. Shah PK, Yano J, Reyes O, Chyu KY, Kaul S, Bisgaier CL, et al. High-dose recombinant apolipoprotein A-I (Milano) mobilizes tissue cholesterol and rapidly reduces plaque lipid and macrophage content in apolipoprotein E-deficient mice: potential implications for acute plaque stabilization. Circulation 2001; 103: 3047-3050
149. Crisby M, Nordin-Fredriksson G, Shah PK, Yano J, Zhu J, Nilsson J. Pravastatin treatment increases collagen content and decreases lipid content, inflammation, metalloproteinases, and cell death in human carotid plaques: implications for plaque stabilization. Circulation 2001; 103: 926-933
150. Shah PK, Kaul S, Nilsson J, Cercek B. Exploiting the vascular protective effects of high-density lipoprotein and its apolipoproteins: an idea whose time for testing is coming, part I. Circulation 2001; 104: 2376-2383
151. Shah PK, Kaul S, Nilsson J, Cercek B. Exploiting the vascular protective effects of high-density lipoprotein and its apolipoproteins: an idea whose time for testing is coming, part II. Circulation 2001; 104: 2498-2502
152. Forrester J, Makkar R, Shah PK. Increasing HDL cholesterol in dyslipidemia by cholesterol ester transfer protein inhibition: an update for clinicians: Circulation 2005 (in press)
153. Li X, Chyu KY, Neto JR, Yano J, Nathwani N, Ferreira C, et al. Differential effects of apolipoprotein A-I-mimetic peptide on evolving and established atherosclerosis in apolipoprotein E-null mice. Circulation 2004 21; 110: 1701-1705
154. Claudel T, Leibowitz MD, Fievet C, Tailleux A, Wagner B, Repa JJ, et al. Reduction of atherosclerosis in apolipoprotein E knockout mice by activation of the retinoid X receptor. Proc Natl Acad Sci USA 2001; 98: 2610-2615
155. Kirkham TC, Williams CM. Endocannabinoid receptor antagonists: potential for obesity treatment. Treat Endocrinol 2004; 3: 345-360